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Abstract 
Introduction: Asprosin is a hormone that was first reported by Romere et al. [2016]. Its secretion is induced in the case of starvation. 
Asprosin promotes hepatic glucose release. There is no literature information available in humans to demonstrate how blood and saliva 
asprosin levels of patients with the newly identified type 2 diabetes mellitus (T2DM) changed after metformin treatment. We aim to 
examine these changes and contribute to the literature in this sense.
Material and methods: A total of 60 individuals: 30 healthy volunteers and 30 newly identified cases of T2DM whose treatment had been 
initiated, were included in the investigation. Blood and saliva sample specimens were carefully taken from both groups. Saliva asprosin 
and serum levels were tested using the ELISA method. Immunohistochemical methods were used to test asprosin formation sites in 
salivary gland tissues.
Results: Similarly increased asprosin levels were observed in patients from the newly diagnosed T2DM group compared with the healthy 
control group (p = 0.003). In the newly defined T2DM group, blood asprosin levels decreased significantly after three months of metfor-
min treatment (p = 0.032). In terms of saliva asprosin levels, when the healthy control group and the newly identified T2DM group were 
compared, saliva asprosin levels were found to be higher in the newly identified T2DM group (p < 0.001). With immunohistochemical 
staining, asprosin immunoreactivity was observed in the submandibular and parotid glands.
Conclusions: In our study, serum and saliva asprosin levels increased significantly in the newly identified individuals with type 2 diabetes, 
which suggests that asprosin could form a critical risk related to T2DM. Higher asprosin levels are an important marker for predicting 
diabetes development, and that this hormone can be signified as a main or target molecule in the treatment of diabetes. (Endokrynol 
Pol 2021; 72 (1): 37–43)
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Introduction
Diabetes, beyond glycaemic control, is a complex and 
chronic disease, the aetiology of which is multifacto-
rial, requiring continuous medical care [1]. There are 
four major types of diabetes: type 1 diabetes mellitus 
(T1DM), type 2 diabetes mellitus (T2DM), gestational 
diabetes mellitus (GDM), and others [2]. As of 2019, 
more than 463 million people are estimated to live with 
diabetes worldwide, and according to the 2019 estimates 
of this figure, the International Diabetes Federation 
has increased the prediction to 578.4 million by 2030; 
it predicts that it will reach 700.2 million by 2045 [3]. 
Among these T2DM is the largest spread with more 
than 90% of patients [4]. Beta-cell dysfunction or an in-
creased hepatic glucose output and insulin resistance 
are important pathophysiological features of T2DM [5]. 
Various antidiabetic drugs, like metformin and 
glucagon-like peptide 1 (GLP-1) receptor analogues, 
show their effects by partially reducing hepatic glucose 
output [4, 6]. Except under specific conditions, usually 
metformin is prescribed as the first drug for the treat-
ment of hyperglycaemia in T2DM patients. When iden-
tified with diabetes, metformin therapy can be initiated 
simultaneously with lifestyle change recommendations 
[7, 8]. Hepatic glucose suppression appears as a better 
treatment agent for T2DM.
Asprosin is a protein consisting of 140 amino acids 
with a C-terminal region cleaved with pro brillin [9]. It 
is secreted from white adipose tissue, and its secretion 
is induced in the case of starvation. Asprosin cAMP 
(G protein-cyclic adenosine monophosphate) — pro-
tein kinase promotes hepatic glucose production via 
the A pathway and thus has a protective effect from 
hypoglycaemia [9, 10]. However, studies with animal 
models have shown that asprosin administration causes 
hyperglycaemia and hyperinsulinaemia [9]. In animal 
models and studies in humans, insulin resistance and 
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mens were treated in the tube with EDTA, shaking gently on ice 
batteries without wasting time, and centrifuged at 4000 rpm for 
10 minutes, then placed in Eppendorf tubes followed by storing 
at –80°C until carrying out the study. The saliva sample specimens 
were transferred to aprotinin tubes and centrifuged under the 
same conditions and kept at –80°C until the working day. Asprosin 
levels in serum and saliva sample specimens, Human (asprosin); 
catalogue number: 201-12-7193 (Sunred Biological Technology Co. 
Ltd, Shanghai, CHINA) was studied by ELISA method following 
the working techniques as mentioned in the kit catalogues. Measur-
ing range of Human Asprosin ELISA kit: 1–300 ng/mL, intra-assay: 
CV value < 10%, inter-assay: CV value < 12%, and sensitivity was 
0.756 ng/mL. An automatic washer Bio-Tek ELX50 (BioTek Instru-
ments, USA) was used for plate washings, and ChroMate Micro-
plate Reader P4300 device (Awareness Technology Instruments, 
USA) was used for absorbance readings. Test results are given in 
ng/mL. The asprosin kit has been shown to measure asprosin in 
saliva sample specimens [13]. We also measured the saliva sample 
specimens according to this method.
Immunohistochemistry
Submandibular and parotid glands from salivary glands were used 
for asprosin immunoreactivity. Archived submandibular and pa-
rotid gland tissue samples of five patients (were not diagnosed), and 
five T2DM patients who had provided submandibular and parotid 
gland tissue samples due to diagnostic purposes were included in 
the study. Sections taken from paraffin blocks with a thickness of 
5–6 mm were placed on PolySync slides. The deparaffinised tissues 
were treated with graded alcohol series using boiled citrate buf-
fer to retrieve antigen at pH 6.0 in a microwave oven (750 W) for 
7 + 5 minutes. These tissues were cooled at 24°C for ~20 minutes 
after boiling and were washed with PBS (Phosphate Buffered 
Saline, P4417, Sigma-Aldrich, USA) for 3 × 5 minutes, followed by 
incubation on hydrogen peroxide block solution for five minutes to 
avoid endogenous peroxidase activity (Hydrogen Peroxide Block, 
TA–125-HP, Lab Vision Corporation, USA). Five-minute Ultra V 
Block (TA–125-UB, Lab Vision Corporation, USA) solution was 
applied to these tissues after they were rinsed with PBS for 
3 × 5 minutes to prevent ground paint followed by continuous 
incubation at 24°C for 1 hour in a moist environment containing 
primary antibody (Polyclonal Antibody to Asprosin, PAA332Hu01, 
Cloud-Clone Corp., USA) diluted by 1/200. Tissues were washed 
3 × 5 minutes with PBS after administration of primary antibody 
and were incubated for 30 minutes at room temperature in a moist 
environment Along with secondry antibody (biotinylated Goat 
Anti-Pollivalent [anti-mouse/rabbit IgG], TP–125-BN, Lab Vision 
Corporation, USA). Tissues were taken into phosphate buffered sa-
line (PBS) after washing for 3 × 5 minutes with PBS and incubating 
with Streptavidin Peroxidase (TS–125-HR, Lab Vision Corporation, 
USA) at room temperature for 30 minutes after secondary antibody 
administration. After dropping the 3-amino-9-ethyl carbazole (AEC) 
substrate + AEC Chromogen (AEC Substrate, TA-015 and HAS, AEC 
Chromogen, TA-002-HAC, Lab Vision Corporation, USA) solution 
into the tissues and after an image signal was obtained in the light 
microscope, washing with PBS was applied simultaneously. Tissues 
were then contrasted using Mayer’s haematoxylin by treating with 
PBS + distilled water and stopped with suitable closure solution 
(Large Volume Vision Mount, TA-125-UG, Lab Vision Corporation, 
USA). The preparations were examined using a Leica DM500 mi-
croscope and photographed (Leica DFC295).
Statistical analysis
The statistical analyses were carried out with SPSS 24 (Statistical 
Package for the Social Sciences version 22.0 (SPSS Inc., Chicago, 
USA). The experimental data were subjected to variance analysis, 
Student’s t-test, descriptive statistical methods, and equivalents. 
Analysis of covariance (ANCOVA) model plus post hoc t-test with 
Bonferroni’s correction was used to compare levels of blood and 
serum asprosin levels have been reported to increase 
in T2DM patients [11]. In another study, it has been 
shown that insulin sensitivity increases as a result of 
the neutralisation of asprosin by specific antibodies 
[9]. Considering all this information, reducing aspro-
sin activity might be considered as a new therapeutic 
potential to treat the diseases related to insulin resis-
tance: obesity, gestational diabetes, polycystic ovary 
syndrome, and especially T2DM. Some studies show 
a relationship between serum asprosin and T2DM in 
humans. However, there is no literature information 
showing the blood and saliva asprosin levels of these 
(the newly identified T2DM) patients and how these 
levels change after metformin treatment. Also, there 
has been no study yet evaluating the effects of metfor-
min, an oral antidiabetic that decreases hepatic glucose 
output, and asprosin, which has a diabetogenic effect 
by increasing hepatic glucose output. Our aim in the 
study is to examine these changes and contribute to the 
literature in this sense.
Material and methods
Participants
Every care was taken to obtain ethical approval from Firat Uni-
versity Non-Interventional Research Ethics Committee before 
the study with the decision dated 24/01/2019 and numbered 
97132852/050.01.04/02/16. A total of 60 individuals: 30 healthy vol-
unteers and 30 the newly identified cases of T2DM, participated 
in the study. Diabetes identification was placed as per the identi-
fication/diagnostic criteria of the American Diabetes Association 
(ADA) [12]. Accordingly, after eight hours of fasting, fasting blood 
glucose ≥ 126 mg/dL, 75 g of oral glucose tolerance test (OGTT) 
second-hour blood glucose ≥ 200 mg/dL, haemoglobin A1c (HbA1c) 
≥ 6.5% or randomly observed individuals with symptoms of hy-
perglycaemia, whose blood sugar was measured as ≥ 200 mg/dL, 
were considered T2DM. [12]. Metformin treatment was started in 
the newly diagnosed T2DM patients at a dose of 2000 mg/day and 
continued for three months. Individuals with a history of diabetes, 
hypertension, any known cardiovascular disease, malignancy, 
use of immunosuppressive drugs, steroids, or acute/chronic liver 
disease, acute/chronic kidney failure, infection, and pregnant or 
mentally retarded patients with socio-cultural communication 
problems were excluded and did not participate in the study.
Sample specimens
Fasting plasma glucose, low-density lipoprotein cholesterol (LDL-
C), triglyceride, alanine aminotransferase (ALT), aspartate amino-
transferase (AST), urea, creatinine, and complete blood count (CBC) 
values were examined in both the T2DM group and the healthy 
control group. To better evaluate the glycaemic status in the T2DM 
group, satiety plasma glucose and HbA1c levels were also evaluated. 
Parameters such as ALT, AST, LDL, triglyceride, urea, creatinine, 
and fasting and postprandial blood glucose levels were carefully 
measured using an Olympus AU 600 (Olympus Optical Co. Ltd, 
Tokyo, Japan) automated analyser using commercially available 
Olympus kits. Haemoglobin, haematocrit, and HbA1c levels were 
measured with a CELL-DYN 3700 (USA) device.
At the time of admission, a 4 ml blood sample specimen and 
4 mL saliva sample specimen from the left antecubital region in 
the healthy control group and the patients were taken into tubes 
containing aprotinin (protease inhibitor). The blood sample speci-
39










saliva asprosin among the groups adjusting for age. In our study, 
statistical significance was accepted as p < 0.05.
Results
The clinical, demographic, and laboratory data of the 
individuals included in the study are summarised in 
Table 1. The average age of the diabetic patient group 
was remarkably high compared to the patients in the 
healthy control group (p < 0.001). In the T2DM group 
and the healthy control group, the ratio of male to 
female was balanced. Blood sugar levels during fast-
ing were higher in the specific group patients having 
diabetes (p < 0.001). No significant variation was noted 
between the group patients considering the tests based 
on liver functions. While LDL levels were significantly 
higher in patients with diabetes compared to the 
healthy control group at the time of the first identifica-
tion (124.2 ± 31.9; 152.03 ± 51.3, p = 0.01, respectively), 
the statistical variations between the group patients 
disappeared after three months of metformin treat-
ment (respectively, 124.2 ± 31.9; 127.9 ± 33.6, p = 0.67). 
Blood asprosin levels were measured, respectively, in 
the healthy control group, during the identification of 
patients with type 2 diabetes, and after three months 
of treatment as 25.16 ± 14.49, 49.52 ± 41.98, and 
27.27 ± 19.77 ng/mL (Tab. 1). In terms of blood asprosin 
levels, when the healthy control group patients and the 
newly identified T2DM group patients was compared, 
the blood asprosin levels were identified statistically 
higher in the newly identified T2DM group (p = 0.003). 
After age adjustment and Bonferroni correction, the 
blood asprosin levels were higher in the newly identi-
fied T2DM group compared to the healthy control 
group patients (p = 0.04). In the newly identified T2DM 
group, blood asprosin levels decreased significantly 
after three months of metformin treatment (p = 0.032). 
When the control group and the three-month treatment 
group were compared for blood asprosin levels the dif-
ferences were statistically non-significant (p = 0.954). 
Saliva asprosin levels are measured respectively in 
the healthy control group patients, during the iden-
tification of patients with type 2 diabetes and after 
3 months of treatment as 23.79 ± 10.27, 45.85 ± 23.07, 
34.41 ± 19.02 ng/mL (Tab. 1, Fig. 2). In terms of saliva 
asprosin levels, when the healthy control group pa-
tients and the newly identified T2DM group patients 
were compared, in the newly identified T2DM group, 
asprosin levels were statistically significant higher 
(p < 0.001). The saliva asprosin levels were higher in 










Age (Years) 30.10 ± 8.8 54.63 ± 10.8 54.63 ± 10.8 < 0.001 < 0.001 > 0.05
Gender (Male/Female) 16/14 17/13 17/13 > 0.05 – –
Systolic BP [mm Hg] 105 ± 20.2         119 ± 17.5       111.1 ± 12.4     < 0.05 – –
Diastolic BP [mm Hg] 67 ± 7.2 76.0 ± 13.2 76 ± 9.3 < 0.05 – –
BMI [kg/m2] 23.6 ± 4.8 26.4 ± 3.6         25.3 ± 4.9 > 0.05 > 0.05 > 0.05
FPG [mg/dL] 89.9 ± 10.7 178.3 ± 47.10 136.10 ± 39.3 ˂ 0.001 ˂ 0.001 ˂ 0.001
PPG [mg/dL] 287 ± 84.9 217.17 ± 77.28 – – ˂ 0.001
AST [U/L] 20.9 ± 11.06 23.3 ± 13.2 21.40 ± 8.93 0.45 0.09 0.22
ALT [UL] 22.6 ± 14.10 29.4 ± 17.8 21.90 ± 13.09 0.10 0.82 0.084
Urea [mg/dL] 25.07 ± 7.9 29.47 ± 8.1 31.37 ± 10.73 0.03 0.01 0.144
Creatinine [mg/dL] 0.67 ± 0.16 0.75 ± 0.24 0.75 ± 0.23 0.18 0.17 0.973
Haemoglobin [gr/dL] 12.7 ± 1.5 14.2 ± 1.78 14.11 ± 1.81 < 0.01 < 0.01 > 0.05
Haematocrit (%) 39.2 ± 3.85 43 ± 5.2 42.3 ± 4.95 0.001 0.008 0.310
LDL-C [mg/dL] 124.2 ± 31.90 152.03 ± 51.3 127.9 ± 33.6 0.01 0.67 0.025
Triglycerides [mg/dL] 204.8 ± 80.126 255.9 ± 150.78 208.9 ± 84.2 0.10 0.84 0.04
HbA1c (%) 7.5 ± 1.6 6.2 ± 1.2 – – ˂ 0.001
Asprosin plasma [ng/mL] 25.16 ± 14.49 49.52 ± 41.98 27.27 ± 19.77 0.003 0.954 0.032
Asprosin saliva [ng/mL] 23.79 ± 10.27 45.85 ± 23.07 34.41 ± 19.02 < 0.001 0.068 < 0.001
P1 — control with DM-0 month comparison; P2 — control with DM-3 months comparison; P3 — DM0. months with DM-3 months comparison; BP — blood pressure; 
BMI — body mass index; FPG — fasting plasma glucose; PPG — postprandial blood glucose; AST — aspartate aminotransferase; ALT — alanine aminotransferase; 
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the newly identified T2DM group compared to the 
healthy control group patients after age adjustment 
and Bonferroni correction (p < 0.001). In the newly 
identified T2DM group, saliva asprosin levels decreased 
remarkably three months post metformin treatment 
(p < 0.001). When the healthy control group patients 
and the three-month treatment group were compared 
in terms of saliva asprosin levels, these differences 
were not statistically significant (p = 0.068). Therefore, 
with immunohistochemical staining for asprosin im-
munoreactivity and checking under light microscope, 
asprosin immunoreactivity was observed in the sub-
mandibular gland and acinar cells in intralobular and 
interlobular canals (Fig. 3A). Asprosin immunoreactivity 
in the parotid gland was observed in intralobular and 
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Figure 2. Asprosin levels in the saliva of all three groups. DM — diabetes mellitus
Figure 3. Asprosin immunoreactivity; intralobular ducts and interlobular ducts in the submandibular (A) and parotid (B) glands
A B
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Asprosin is secreted from white adipose tissues, pancre-
atic b-cells, and salivary glands and causes the release of 
hepatic glucose [9, 10, 14–16]. In the fasting state, plasma 
asprosin level increases, and it decreases after eating [9]. 
Studies in humans and animal models show that serum 
asprosin levels increase in patients with insulin resis-
tance and/or T2DM [11]. In another study, it was shown 
that insulin sensitivity increased as a result of inhibition 
of asprosin with specific antibodies [9]. However, in 
a study by Zhang et al. serum asprosin levels were not 
found to be associated with other glucose metabolism 
parameters other than HbA1c in individuals with nor-
mal glucose tolerance and in newly identified diabetics 
[11]. When all of these human and animal studies are 
evaluated as a whole, it can be seen that there may be 
a strong induction-effect relationship between T2DM 
and asprosin, showing that serum asprosin levels can 
act as an indicator for the early identification of T2DM 
and may also be an important hormone as a treatment 
goal. In light of this information, our study aimed to 
identify the possible correlation between asprosin and 
T2DM in newly identified patients and to document 
how this relationship was affected after metformin 
treatment, by measuring both plasma and saliva aspro-
sin levels.
Previous studies have shown that plasma asprosin 
levels increase in the newly identified diabetic patients 
[11]. In our study, plasma asprosin levels were signifi-
cantly increased at the time of identification compared 
to the control group patients (Tab. 1), and this was 
statistically significant. As in previous studies, saliva 
asprosin levels in this study were significantly higher 
compared to the control group patients. Our results 
regarding the relationship between T2DM and aspro-
sin are compatible with previous studies. Ugur et al. 
showed that asprosin is also expressed from salivary 
glands [16]. We also supported immunohistochemically 
that asprosin is expressed in both submandibular and 
parotid glands, in support of this study (Fig. 3). The 
point that makes our study superior to other studies 
is that it revealed the possible relationship between 
T2DM and asprosin by simultaneously measuring both 
plasma and saliva asprosin levels. The simultaneous 
elevation of both plasma and saliva asprosin levels in 
individuals with new T2DM identification suggests 
that the relationship with T2DM may be closer than 
predicted. Another advantage of our study over others 
is that pre-treatment and post-treatment asprosin levels 
were measured and compared in the newly identified 
T2DM patients. As mentioned above, almost all treat-
ment guidelines related to diabetes, along with lifestyle 
changes and dietary recommendations, recommend 
metformin as the first drug in treatment if there are no 
contraindications [7, 8]. Guided by this information, 
we randomly selected our patient group among those 
receiving metformin therapy. There are several com-
mercial forms of metformin, and so, to eliminate the 
heterogeneity between commercial forms and not to 
discuss the results of our study within this aspect, we 
selected patients from among those who used only one 
commercial preparation. When we evaluated the results 
of the study, after three months of metformin treatment, 
we found that both plasma and saliva asprosin levels 
decreased significantly compared to the pre-treatment 
period. When we compare the three-month post-treat-
ment group with the healthy control group patients, we 
found that the previous statistical difference in terms 
of plasma and saliva asprosin levels disappeared. This 
showed that asprosin levels decreased with treatment. 
Although asprosin levels decreased with treatment, 
they did not fall below the asprosin levels of the healthy 
control group patients. Metformin lowers blood glucose 
by several mechanisms. However, glucose lowering has 
its greatest effect by inhibiting gluconeogenesis and 
decreasing hepatic glucose output [17–19]. Asprosin, on 
the other hand, promotes hepatic glucose production 
via the G protein-cyclic adenosine monophosphate 
(cAMP) — protein kinase A (PKA) pathway, thereby 
increasing hepatic glucose output. In a sense, it has 
a protective effect from hypoglycaemia [9, 10]. Asprosin 
and metformin play an important role in maintaining 
the glucose balance in the body, although they have 
an opposite effect on different pathways. But do aspro-
sin and metformin interact via an unknown pathway 
in maintaining this balance? The interaction of asprosin 
with other appetising and glucogenic hormones in the 
mediation of food intake followed by hepatic glucose 
release is not fully understood because hormones like 
norepinephrine, epinephrine, glucocorticoids, and 
glucagon are well known to increase glucose release 
levels from hepatocytes [9]. It is also interesting that 
Romere et al. reported that asprosin treatment did not 
affect the above-mentioned glucogenic hormone levels 
[9]. It is also known as general information that gluca-
gon can exhibit its glucogenic effects by activating the 
G protein–cAMP-PKA axis [9]. However, Romere et al. 
showed that there is no change in the glucogenic effects 
of asprosin on hepatocytes by inhibiting the glucagon 
receptor [9]. We believe that broader molecular studies 
are needed to elucidate these issues, although some 
studies suggest that asprosin may be a hypoglycae-
mia-protective hormone, such as a contra-regulatory 
hormone, although most studies show that asprosin 
contributes to diabetes formation [9, 10]. Returning 
to the results of our study, we found that after three 
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formin, HbA1c decreased to a statistical significance 
compared to the pre-treatment period. Simultaneously, 
we found serum and saliva asprosin levels to be low. 
This relationship between HbA1c and asprosin was 
supportive of the study conducted by Zhang et al. [11]. 
It is known that chronic and low-grade inflamma-
tion occurring in hyperlipidaemic conditions causes li-
potoxicity in b-cells of the pancreas, and this lipotoxicity 
plays a causal role in b-cell dysfunction [20]. However, 
the mechanisms underlying b-cell dysfunction due to 
hyperlipidaemia have not been fully investigated. To 
enlighten this issue, according to the hypothesis pro-
posed by Taeseung et al., asprosin induced by hyperlipi-
daemia contributed to the development of T2DM with 
b-cell dysfunction [15]. As assumed, they showed that 
glucose-induced insulin secretion was impaired, and 
apoptosis increases with inflammation caused by treat-
ing mouse insulinoma 6 (MIN6) and human primary 
islet cells with recombinant asprosin [15]. In their study, 
Zhang et al. displayed that as serum triglyceride levels 
increase, asprosin levels increase simultaneously [11]. 
This study signifies that triglyceride levels were higher 
at the time of identification in patients newly identified 
with T2DM in comparative identity to the control group 
patients, and the asprosin levels that we measured 
simultaneously in plasma and saliva were also high. 
We observed that both triglyceride levels and asprosin 
levels had decreased level after 90 days of treatment. In 
our study, there was also a similar relationship between 
LDL-C and asprosin. The findings we obtained were 
consistent with the results obtained by Zhang et al. [11] 
and Tang et al. [20], while Zhang et al. [11] did not find 
any relationship between diastolic and systolic blood 
pressures and asprosin levels. This study found higher 
diastolic and systolic blood pressures in the newly 
identified T2DM group patients in comparison with 
the healthy control group patients. Serum and saliva 
asprosin levels were accompanied by these high find-
ings. These findings suggest that there may also be a link 
between hypertension and asprosin levels. Of course, 
this link must be revealed in more detail with further 
studies. The relationship between asprosin levels and 
obesity has been demonstrated in previous studies. For 
example, Xinyue et al. [21] showed that asprosin levels 
increase as the body mass index (BMI) increases numeri-
cally although there is no statistical difference in terms 
of BMI between the groups. In another study, which 
included 117 obese people with BMI > 35 kg/m2 and 
57 healthy individuals, fasting asprosin levels displayed 
a significantly higher level in obese patients than in 
healthy patients [22]. Because there was no statisti-
cal difference in terms of BMI between the groups in 
our study, we did not consider it appropriate to make 
a comparison within this aspect. 
Our study has several important limitations. The 
first of these is the small number of cases. The second 
is that the patient follow-up times are short. The third 
is that our post-treatment evaluations were made only 
in patients using metformin, and the fourth is the mean 
age of our patients, and that the healthy control group 
patients were different from each other. However, 
despite these limitations, considering our pre- and 
post-treatment evaluations, our study is the first study 
in this sense. However, we believe that studies with 
a larger number of patients and longer follow-up are 
needed to improve these evaluations. 
Conclusion
This study showed that serum and saliva asprosin 
levels significantly increased in newly identified indi-
viduals with T2DM. The data of this study show that 
asprosin could be a potential risk factor related to the 
development of T2DM. In light of these data, we think 
that serum and saliva asprosin level measurements 
are an important indicator for predicting the develop-
ment of diabetes, and this hormone can be evaluated 
as a target molecule to treat diabetes.
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